Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Sport courts biophysical science innovations in rolling R&D programme:

This article was originally published in Clinica

Executive Summary

Biophysical science innovations resulting from research conducted on the fringe of healthcare R&D are being engaged by UK Sport to support athletic performance. Eight "innovation partner" industry and university sector organisations - examples of "expertise in the fields of engineering, technology and human sciences" - have been chosen to collaborate with its Research and Innovation department, in a rolling development programme. Projects include: active and passive methods of body cooling (the University of Portsmouth's department of sport and exercise science is said to be a leader in thermal science research); optimal hydration; and biochemical recovery strategies. UK Sport is the government's leading sports development body.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel